Drawing for ESSANTIA

USPTO serial 87521932

ESSANTIA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
EVANKO, PATRICIA MALESARDI
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ESSANTIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and bodyACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 8, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 8, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 13, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2020EX5GSOU EXTENSION 5 GRANTED
Aug 12, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 24, 2020EXT5SOU EXTENSION 5 FILED
Jul 24, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 28, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 24, 2020EX4GSOU EXTENSION 4 GRANTED
Jan 24, 2020EXT4SOU EXTENSION 4 FILED
Jan 24, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 8, 2019DOCKASSIGNED TO EXAMINER
Jun 18, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 14, 2019EX3GSOU EXTENSION 3 GRANTED
Jun 14, 2019EXT3SOU EXTENSION 3 FILED
Jun 14, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 25, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 23, 2019EX2GSOU EXTENSION 2 GRANTED
Jan 23, 2019EXT2SOU EXTENSION 2 FILED
Jan 23, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 21, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 19, 2018EX1GSOU EXTENSION 1 GRANTED
Jul 19, 2018EXT1SOU EXTENSION 1 FILED
Jul 19, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 30, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 5, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 15, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 30, 2017ALIEASSIGNED TO LIE
Oct 13, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2017XAECEXAMINER'S AMENDMENT ENTERED
Oct 13, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 13, 2017GNEAEXAMINERS AMENDMENT E-MAILED
Oct 13, 2017CNEAEXAMINERS AMENDMENT -WRITTEN
Oct 5, 2017DOCKASSIGNED TO EXAMINER
Jul 15, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 13, 2017NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance